Abstract
Purpose
Identifying clinically relevant comorbidities and their effect on health-related quality of life (HRQoL) outcomes among men with advanced prostate cancer (APC) can inform patient care and improve outcomes; however, this is poorly understood. The aim of this observational study was to examine the prevalence of comorbidities, and the relationship of comorbidity burden to HRQoL and other patient-reported outcomes (PROs) among men with APC.
Methods
Participants were 192 men (average age 68.8) with APC (stage III or IV) who completed a psychosocial battery including measures of sociodemographic factors, HRQoL and other PROs, and the Charlson Comorbidity Index (CCI). Hierarchical multiple regression analysis was used to examine the relationships between CCI, HRQOL, and PROs.
Results
The vast majority (82%) of participants had at least one comorbidity, with the most common being: hypertension (59%), connective tissue disease or arthritis (31%), diabetes (24%), and problems with kidneys, vision, or another organ (24%). After controlling for covariates, regressions showed that a higher CCI score was significantly associated with worse HRQoL (p < 0.001), lower levels of positive affect (p < 0.05), and higher levels of depression (p < 0.05), fatigue (p < 0.001), pain (p < 0.01), stress (p < 0.01), and cancer-specific distress (p < 0.05).
Conclusions
Comorbidities were common among men with APC, and a greater CCI score was associated with detriments in several domains of HRQoL and other PROs. Our findings show the need to address comorbidities in the presence of a cancer diagnosis and subsequent treatment.
Trial registration clinicalTrials.gov identifier
NCT03149185.
Similar content being viewed by others
Data availability
The data are currently used for secondary analyses and manuscript development. The data that support the study may be available upon request with permission from the researchers who collected the data.
References
Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database, Cancer Stat Facts: Prostate Cancer. 2017-2018, National Cancer Institute (NCI),: Online www.seer.cancer.gov
SEER (n.d.) Cancer stat facts: prostate cancer. National Cancer Institute, Bethesda, MD. https://seer.cancer.gov/statfacts/html/prost.html
Droz JP et al (2010) Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 106(4):462–469
Michaelson MD et al (2008) Management of complications of prostate cancer treatment. CA Cancer J Clin 58(4):196–213
Spratt DE et al (2021) Treating the patient and not just the cancer: therapeutic burden in prostate cancer. Prostate Cancer Prostatic Dis 24(3):647–661
Rawla P (2019) Epidemiology of Prostate Cancer. World journal of oncology 10(2):63–89
Bernard B et al (2020) Impact of age at diagnosis of de novo metastatic prostate cancer on survival. Cancer 126(5):986–993
Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34
Divo MJ, Martinez CH, Mannino DM (2014) Ageing and the epidemiology of multimorbidity. Eur Respir J 44(4):1055–1068
Ward BW, Schiller JS, Goodman RA (2014) Multiple chronic conditions among US adults: a 2012 update. Prev Chronic Dis 11:E62
Koroukian SM, Murray P, Madigan E (2006) Comorbidity, disability, and geriatric syndromes in elderly cancer patients receiving home health care. J Clin Oncol 24(15):2304–2310
Chamie K et al (2012) Comorbidities, treatment and ensuing survival in men with prostate cancer. J Gen Intern Med 27(5):492–499
Matthes KL et al (2018) Impact of comorbidities at diagnosis on prostate cancer treatment and survival. J Cancer Res Clin Oncol 144(4):707–715
Daskivich TJ et al (2013) Effect of age, tumor risk, and comorbidity on competing risks for survival in a US population-based cohort of men with prostate cancer. Ann Int Med 158(10):709–717
Daskivich T et al (2010) Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer. Arch Intern Med 170(15):1396–1397
Fortin M et al (2004) Multimorbidity and quality of life in primary care: a systematic review. Health Qual Life Outcomes 2(1):51
Wen W et al (2021) Racial disparities in mortality for patients with prostate cancer after radical prostatectomy. Cancer 127(9):1517–1528
Price JH et al (2013) Racial/ethnic disparities in chronic diseases of youths and access to health care in the United States. Biomed Res Int 2013:787616–787616
Penedo FJ et al (2020) Technology-Based Psychosocial Intervention to Improve Quality of Life and Reduce Symptom Burden in Men with Advanced Prostate Cancer: Results from a Randomized Controlled Trial. Int J Behav Med 27(5):490–505
Penedo FJ et al (2021) Effects of web-based cognitive behavioral stress management and health promotion interventions on neuroendocrine and inflammatory markers in men with advanced prostate cancer: A randomized controlled trial. Brain Behav Immun 95:168–177
Benzo RM, Moreno PI, Noriega-Esquives B, Otto AK, Penedo FJ (2022) Who benefits from an eHealth-based stress management intervention in advanced prostate cancer? Results from a randomized controlled trial. Psycho-oncology 31(12):2063–2073. https://doi.org/10.1002/pon.6000
Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–98
Sun L et al (2021) Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer. JAMA Netw Open 4(2):e210070–e210070
Charlson ME et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383
Cella DF et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579
Cella D et al (2007) The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 45(5 Suppl 1):S3–S11
Clover K et al (2018) PROMIS depression measures perform similarly to legacy measures relative to a structured diagnostic interview for depression in cancer patients. Qual Life Res 27(5):1357–1367
Hann DM et al (1998) Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res 7(4):301–310
Melzack R (1987) The short-form McGill Pain Questionnaire. Pain 30(2):191–197
Kahl C, Cleland JA (2005) Visual analogue scale, numeric pain rating scale and the McGill pain Questionnaire: an overview of psychometric properties. Phys Therapy Rev 10(2):123–128
Cohen S, Kamarck T, Mermelstein R (1983) A global measure of perceived stress. J Health Soc Behav 24(4):385–396
Weiss DS, Marmar CR (1997) The Impact of Event Scale—Revised. Assessing psychological trauma and PTSD. The Guilford Press, New York, NY, US, pp 399–411
Stanton AL et al (2005) Outcomes from the Moving Beyond Cancer psychoeducational, randomized, controlled trial with breast cancer patients. J Clin Oncol 23(25):6009–6018
Bradburn NM, Noll CE (1969) The structure of psychological well-being. Aldine Pub, Chicago
George D, Mallery P (2010) SPSS for Windows step by step: a simple guide and reference, 17.0 update, 10th edn. Allyn & Bacon, Boston
Kim H-Y (2013) Statistical notes for clinical researchers: assessing normal distribution (2) using skewness and kurtosis. Restorative Dentist Endodontics 38(1):52–54
Jeong Y, Jung MJ (2016) Application and interpretation of hierarchical multiple regression. Orthoped Nurs 35(5):338–341. https://doi.org/10.1097/NOR.0000000000000279
Xiao H et al (2013) Construction of a comorbidity index for prostate cancer patients linking state cancer registry with inpatient and outpatient data. J Registry Manag 40(4):159–164
Chambers SK et al (2017) Trajectories of quality of life, life satisfaction, and psychological adjustment after prostate cancer. Psychooncology 26(10):1576–1585
Reeve BB et al (2014) Impact of comorbidity on health-related quality of life after prostate cancer treatment: combined analysis of two prospective cohort studies. BJU Int 114(6b):E74–E81
Arredondo SA et al (2006) Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: Data from CaPSURE. Urology 67(3):559–565
van Stam MA et al (2020) Patient-reported Outcomes Following Treatment of Localised Prostate Cancer and Their Association with Regret About Treatment Choices. Eur Urol Oncol 3(1):21–31
Mazimba S, Peterson, PN (2021) JAHA spotlight on racial and ethnic disparities in cardiovascular disease. J Am Heart Assoc 10(17):e023650. https://doi.org/10.1161/JAHA.121.023650
Chowdhury-Paulino IM, Ericsson C, Vince R Jr, Spratt DE, George DJ, Mucci LA (2022) Racial disparities in prostate cancer among black men: epidemiology and outcomes. Prostate Cancer Prostatic Dis 25(3):397–402. https://doi.org/10.1038/s41391-021-00451-z
Borno H et al (2019) All Men Are Created Equal: Addressing Disparities in Prostate Cancer Care. Am Soc Clin Oncol Educ Book 39:302–308
Acknowledgements
The authors thank the patients who participated in the study, as well as the staff who recruited patients and worked continuously on delivering and improving care.
Funding
This study was supported by a National Cancer Institute (NCI) grant (R01CA157809) awarded to Dr. Frank Penedo. Dr. Roberto Benzo was supported by an NCI Training Grant (T32CA251064). Dr. Rina Fox was supported by the NCI (K08247973). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Study design and data collection were performed by Frank Penedo, Patricia Moreno, Rina Fox, Emily Walsh, Betina Yanez, and Laura Oswald. Data analyses were performed by Roberto Benzo, Raymond Balise, and Frank Penedo. The first draft of the manuscript was written by Roberto Benzo and Carlos Silvera, and all authors commented on subsequent versions. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethical approval
All study procedures that involved human participants were following the ethical standards of the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study procedures were approved by the Institutional Review Board at Northwestern University.
Consent to participate
Informed consent was obtained from all individual participants in the study.
Competing interests
The authors have no conflicts of interest to disclose.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Benzo, R.M., Moreno, P.I., Fox, R.S. et al. Comorbidity burden and health-related quality of life in men with advanced prostate cancer. Support Care Cancer 31, 496 (2023). https://doi.org/10.1007/s00520-023-07962-6
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00520-023-07962-6